Cargando…

A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats

Non-alcoholic steatohepatitis (NASH) is a recognized risk factor for liver fibrosis and malignancies, and is associated with features of metabolic syndrome, such as obesity and insulin resistance (IR). We previously demonstrated that the disturbance of connexin 32 (Cx32), a gap junctional protein of...

Descripción completa

Detalles Bibliográficos
Autores principales: Naiki-Ito, Aya, Kato, Hiroyuki, Naiki, Taku, Yeewa, Ranchana, Aoyama, Yoshinaga, Nagayasu, Yuko, Suzuki, Shugo, Inaguma, Shingo, Takahashi, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655588/
https://www.ncbi.nlm.nih.gov/pubmed/32833043
http://dx.doi.org/10.1007/s00204-020-02873-5
_version_ 1783608228784898048
author Naiki-Ito, Aya
Kato, Hiroyuki
Naiki, Taku
Yeewa, Ranchana
Aoyama, Yoshinaga
Nagayasu, Yuko
Suzuki, Shugo
Inaguma, Shingo
Takahashi, Satoru
author_facet Naiki-Ito, Aya
Kato, Hiroyuki
Naiki, Taku
Yeewa, Ranchana
Aoyama, Yoshinaga
Nagayasu, Yuko
Suzuki, Shugo
Inaguma, Shingo
Takahashi, Satoru
author_sort Naiki-Ito, Aya
collection PubMed
description Non-alcoholic steatohepatitis (NASH) is a recognized risk factor for liver fibrosis and malignancies, and is associated with features of metabolic syndrome, such as obesity and insulin resistance (IR). We previously demonstrated that the disturbance of connexin 32 (Cx32), a gap junctional protein of hepatocytes, exacerbated NASH in Cx32 dominant-negative transgenic (Cx32ΔTg) rats fed methionine choline-deficient diet (MCDD). MCDD is well-established means of inducing NASH in rodents; however, the Cx32ΔTg-MCDD NASH model does not reproduce obesity and IR. In this study, we aimed to establish an improved NASH model. Eight-week-old male Cx32ΔTg and wild-type (Wt) rats received a high-fat diet (HFD) with dimethylnitrosamine (DMN) for 12 weeks. The HFD with DMN led to gains in body, liver, and visceral fat weights in both genotypes. IR was significantly greater in Cx32ΔTg than in Wt rats. Elevation of serum hepatic enzymes (AST, ALT), inflammatory cytokine expressions (Tnfα, Il-6, Tgf-β1, Il-1β, Timp2, and Col1a1), steatohepatitis, and fibrosis were significantly greater in Cx32ΔTg as compared with Wt rats. Regarding carcinogenesis, the number and area of glutathione S-transferase placental form (GST-P)-positive preneoplastic hepatic foci were significantly increased in Cx32ΔTg versus Wt rats. Moreover, activation of NF-κB and JNK contributed to the progression of NASH in Cx32ΔTg rats. These results suggest that Cx32 dysfunction promoted the progression of NASH, metabolic syndrome, and carcinogenesis. Therefore, the novel Cx32ΔTg–HFD–DMN NASH model may be a rapid and useful tool for evaluating the progression of NASH. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00204-020-02873-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7655588
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-76555882020-11-12 A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats Naiki-Ito, Aya Kato, Hiroyuki Naiki, Taku Yeewa, Ranchana Aoyama, Yoshinaga Nagayasu, Yuko Suzuki, Shugo Inaguma, Shingo Takahashi, Satoru Arch Toxicol Organ Toxicity and Mechanisms Non-alcoholic steatohepatitis (NASH) is a recognized risk factor for liver fibrosis and malignancies, and is associated with features of metabolic syndrome, such as obesity and insulin resistance (IR). We previously demonstrated that the disturbance of connexin 32 (Cx32), a gap junctional protein of hepatocytes, exacerbated NASH in Cx32 dominant-negative transgenic (Cx32ΔTg) rats fed methionine choline-deficient diet (MCDD). MCDD is well-established means of inducing NASH in rodents; however, the Cx32ΔTg-MCDD NASH model does not reproduce obesity and IR. In this study, we aimed to establish an improved NASH model. Eight-week-old male Cx32ΔTg and wild-type (Wt) rats received a high-fat diet (HFD) with dimethylnitrosamine (DMN) for 12 weeks. The HFD with DMN led to gains in body, liver, and visceral fat weights in both genotypes. IR was significantly greater in Cx32ΔTg than in Wt rats. Elevation of serum hepatic enzymes (AST, ALT), inflammatory cytokine expressions (Tnfα, Il-6, Tgf-β1, Il-1β, Timp2, and Col1a1), steatohepatitis, and fibrosis were significantly greater in Cx32ΔTg as compared with Wt rats. Regarding carcinogenesis, the number and area of glutathione S-transferase placental form (GST-P)-positive preneoplastic hepatic foci were significantly increased in Cx32ΔTg versus Wt rats. Moreover, activation of NF-κB and JNK contributed to the progression of NASH in Cx32ΔTg rats. These results suggest that Cx32 dysfunction promoted the progression of NASH, metabolic syndrome, and carcinogenesis. Therefore, the novel Cx32ΔTg–HFD–DMN NASH model may be a rapid and useful tool for evaluating the progression of NASH. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00204-020-02873-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-08-24 2020 /pmc/articles/PMC7655588/ /pubmed/32833043 http://dx.doi.org/10.1007/s00204-020-02873-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Organ Toxicity and Mechanisms
Naiki-Ito, Aya
Kato, Hiroyuki
Naiki, Taku
Yeewa, Ranchana
Aoyama, Yoshinaga
Nagayasu, Yuko
Suzuki, Shugo
Inaguma, Shingo
Takahashi, Satoru
A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats
title A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats
title_full A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats
title_fullStr A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats
title_full_unstemmed A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats
title_short A novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats
title_sort novel model of non-alcoholic steatohepatitis with fibrosis and carcinogenesis in connexin 32 dominant-negative transgenic rats
topic Organ Toxicity and Mechanisms
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655588/
https://www.ncbi.nlm.nih.gov/pubmed/32833043
http://dx.doi.org/10.1007/s00204-020-02873-5
work_keys_str_mv AT naikiitoaya anovelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT katohiroyuki anovelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT naikitaku anovelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT yeewaranchana anovelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT aoyamayoshinaga anovelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT nagayasuyuko anovelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT suzukishugo anovelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT inagumashingo anovelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT takahashisatoru anovelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT naikiitoaya novelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT katohiroyuki novelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT naikitaku novelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT yeewaranchana novelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT aoyamayoshinaga novelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT nagayasuyuko novelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT suzukishugo novelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT inagumashingo novelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats
AT takahashisatoru novelmodelofnonalcoholicsteatohepatitiswithfibrosisandcarcinogenesisinconnexin32dominantnegativetransgenicrats